Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

25.59
-0.1132-0.44%
Volume:1K
Turnover:29.50K
Market Cap:5.12M
PE:- -
High:25.59
Open:25.51
Low:25.51
Close:25.70
52wk High:27.94
52wk Low:22.63
Shares:200.00K
Float Shares:200.00K
Volume Ratio:1.52
T/O Rate:0.58%
Dividend:0.41
Dividend Rate:1.61%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Hims & Hers (HIMS) Stock Looks Like A Bargain After A 396% Run

Simply Wall St.
·
Aug 23

Market Chatter: Hims & Hers Health Faces Nearly $75,000 Bill From Card Disputes

MT Newswires Live
·
Aug 22

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live
·
Aug 22

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 22

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Dow Jones
·
Aug 22

Scholar Rock price target raised to $64 from $58 at Wedbush

TIPRANKS
·
Aug 21

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

TIPRANKS
·
Aug 21

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026

THOMSON REUTERS
·
Aug 21

Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating

Reuters
·
Aug 21

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Hims & Hers Health (HIMS) Lifts Guidance As Scrutiny Builds, Is The Stock Fully Valued?

Simply Wall St.
·
Aug 21

Hims & Hers Chief Legal Officer Soleil Boughton Disposes of USD 691,808 in Common Shares

Reuters
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20